The company is seeking funding for asset purchase, R&D, clinical trial expenses, and general administrative expenses to complete the clinical trial and achieve FDA clearance within the next 24 months. Over $50 million has already been invested in the Lumivascular platform, establishing a strong technological and regulatory foundation. This investment supports a differentiated, game-changing technology with a compelling market opportunity, addressing unmet clinical needs in the treatment of coronary CTOs, while offering the potential for meaningful impact and investor returns.